A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis

Oncogene

Volumn 29, Issue 22, 2010, Pages 3287-3296

  Odvody, J ^a   Vincent, T ^a   Arrate, M P ^a   Grieb, B ^a   Wang, S ^b   Garriga, J ^b   Lozano, G ^c   Iwakuma, T ^d   Haines, D S ^b   Eischen, C M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lymphoma; Mdm2; MTBP; Myc; P53

Indexed keywords

BINDING PROTEIN; MDM2 BINDING PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; CARRIER PROTEIN; MTBP PROTEIN, MOUSE; PROTEIN MDM2;

ANIMAL CELL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEFICIENCY; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL GROWTH; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CARRIER PROTEINS; CELL GROWTH PROCESSES; CELLS, CULTURED; FEMALE; GENES, MYC; GENES, TUMOR SUPPRESSOR; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

MUS; MUS MUSCULUS;

EID: 77953230036     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.82     Document Type: Article

References (19)

1. Alt JR, Greiner TC, Cleveland JL, Eischen CM. (2003). Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 22: 1442-1450.
2. Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A et al. (2003). Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell 11: 905-914.
3. Boyd MT, Vlatkovic N, Haines DS. (2000). A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J Biol Chem 275: 31883-31890.
4. Brady M, Vlatkovic N, Boyd MT. (2005). Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol 25: 545-553.
5. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. (2006). High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9: 313-325.
6. Eischen CM, Alt JR, Wang P. (2004). Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lympho-ma development. Oncogene 23: 8931-8940.
7. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669.
8. Eischen CM, Woo D, Roussel MF, Cleveland JL. (2001). Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 21: 5063-5070.
9. Iwakuma T, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM et al. (2008). Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene 27: 1813-1820.
10. Langdon WY, Harris AW, Cory S, Adams JM. (1986). The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47: 11-18.
11. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. (1995). A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690.
12. Marine JC, Lozano G. (2010). Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17: 93-102.
13. Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC et al. (2007). Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res 67: 10736-10743.
14. Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA et al. (2005). Targeting ornithine decarboxylase in Myc-induced lympho-magenesis prevents tumor formation. Cancer Cell 7: 433-444.
15. Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA et al. (2006). MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res 66: 6598-6605.
16. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. (1999). INK4a/ARF mutations accelerate lymphoma-genesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670-2677.
17. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044.
18. Wang P, Lushnikova T, Odvody J, Greiner TC, Jones SN, Eischen CM. (2008). Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 27: 1590-1598.
19. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ et al. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.